RAPP Overview

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is54.60 USD with a low forecast of 40.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rapport Therapeutics Inc revenue for the last quarter amounts to -38.51M USD, increased 63.72

Rapport Therapeutics Inc. EPS for the last quarter amounts to -24870000.00 USD, increased 69.51

Rapport Therapeutics Inc (RAPP) has 84 emplpoyees as of March 11 2026.

Today RAPP has the market capitalization of 1.41B USD.